This SPORE application submitted in response to the RFA from the National Cancer Institute, will take advantage of the strengths in prostate cancer research and treatment that exist at the Robert H. Lurie Comprehensive Cancer Center. The SPORE will provide the infrastructure to bring together basic scientists and clinicians to rapidly test new approaches in the prevention, early detection, diagnosis and treatment of human prostate cancer. The specific themes of the SPORE are: 1. Cell and molecular biology of prostate cancer 2. Prevention and risk factors in prostate cancer development 3. Prostate cancer innovative therapeutics and rehabilitation 4. Quality of life and outcomes research in prostate cancer The SPORE application consists of six principal research projects, three career development projects, five pilot projects and four Core facilities to support the research. The principal research projects are: 1) Clusterin and resistance to apoptosis (Lee), 2) Suppressive role of calreticulin in prostate cancer (Wang), 3) Prostate cancer dependent generation of angiostatin 4.5 (Soff), 4) Molecular mechanisms of erectile dysfunction (McVary), 5) Effects of lycopene on prostatic tissue (Gann), 6) Quality of life item banking in prostate cancer (Cella). The Core facilities include: Administration, Tissue Resource, Clinical and Biostatistical Cores. The investigators selected to be part of the SPORE Program come from a variety of disciplines ranging from Clinical Programs to Chemical Engineering, Pathology and Chemistry. To maintain meaningful communication between investigators, we will have monthly meetings of SPORE investigators, an annual retreat and monthly meetings of the Executive Committee. Based on the infrastructure described, our large patient population and our track record of productivity, we believe that the Robert H. Lurie Comprehensive Cancer Center is well suited for the SPORE program.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-V (J1))
Program Officer
Hruszkewycz, Andrew M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northwestern University at Chicago
Schools of Medicine
United States
Zip Code
Hung, Michelle E; Lenzini, Stephen B; Stranford, Devin M et al. (2018) Enrichment of Extracellular Vesicle Subpopulations Via Affinity Chromatography. Methods Mol Biol 1740:109-124
Weiner, Adam B; Tsai, Kyle P; Keeter, Mary-Kate et al. (2018) The Influence of Decision Aids on Prostate Cancer Screening Preferences: A Randomized Survey Study. J Urol 200:1048-1055
Nettey, Oluwarotimi S; Walker, Austin J; Keeter, Mary Kate et al. (2018) Self-reported Black race predicts significant prostate cancer independent of clinical setting and clinical and socioeconomic risk factors. Urol Oncol 36:501.e1-501.e8
Xu, Li; Gordon, Ryan; Farmer, Rebecca et al. (2018) Precision therapeutic targeting of human cancer cell motility. Nat Commun 9:2454
Zhang, Qiang; Helfand, Brian T; Carneiro, Benedito A et al. (2018) Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-? Insensitive Genetically Targeted CD8+ T-cells Derived from Patients with Metastatic Castrate-resistant Disease. Eur Urol 73:648-652
Pascal, Laura E; Masoodi, Khalid Z; Liu, June et al. (2017) Conditional deletion of ELL2 induces murine prostate intraepithelial neoplasia. J Endocrinol 235:123-136
Dominguez, Donye; Ye, Cong; Geng, Zhe et al. (2017) Exogenous IL-33 Restores Dendritic Cell Activation and Maturation in Established Cancer. J Immunol 198:1365-1375
Murphy, A B; Nyame, Y A; Batai, K et al. (2017) Does prostate volume correlate with vitamin D deficiency among men undergoing prostate biopsy? Prostate Cancer Prostatic Dis 20:55-60
Loeb, Stacy; Shin, Sanghyuk S; Broyles, Dennis L et al. (2017) Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. BJU Int 120:61-68
Zhang, Minghui; Dominguez, Donye; Chen, Siqi et al. (2017) WEE1 inhibition by MK1775 as a single-agent therapy inhibits ovarian cancer viability. Oncol Lett 14:3580-3586

Showing the most recent 10 out of 209 publications